MARRCH Minnesota Society of Addiction Medicine Presents. Addiction as a Brain Disease
|
|
- Evan Black
- 5 years ago
- Views:
Transcription
1 MARRCH 2008 Minnesota Society of Addiction Medicine Presents Addiction as a Brain Disease Gavin Bart, MD Charles Reznikoff, MD Steven Fu, MD, MSCE David Frenz, MD, MS October 22, 2008
2 Schedule 10:00-12:00 Gavin Bart Introduction Addiction as a Brain Disease: opiate dependence 1:00-1:40 Charels Reznikoff Marijuana: psychiatric and medical consequences 1:50-2:30 Steven Fu Smoking cessation in alcohol dependence 3:00-3:40 David Frenz Alcohol dependence treatment Benzodiazepine dependence treatment 3:50-4:30 Gavin Bart Ending Q&A session
3 A Lesson in Civics September 29 House rejects bailout October 1 Senate passes bailout October 3 bailout signed into law as Emergency Economic Stabilization Act of 2008
4 Article 1 Section 7. All bills for raising revenue shall originate in the House of Representatives; but the Senate may propose or concur with amendments as on other Bills.
5 What the Senate Passed Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 Bailout was an amendment
6 The Costs Bailout bill $700,000,000,000 Alcohol, tobacco, and other drugs $500,000,000,000 Per year What is the real bailout?
7 What does it mean for you? Equal mental health and addiction coverage No hospitalization limits No limited sessions Equal copays Pre-defined list of covered diseases Who is a qualified provider? Economic bottom-line gets covered Evidence-based practice Results will be expected and tracked
8 Treating Addiction as a Brain Disease The Case of Opiate Dependence If addiction is a disease then, Addiction must be treated like one
9 The Burden of Addiction 12.4% of all deaths in the world are related to substance use When does death occur? >50% early life for drugs 65% before age 60 for alcohol 70% after age 60 for tobacco WHO 2002
10 1-Year Prevalence of Drug Use National Survey on Drug Use and Health 2006 Alcohol Use Alcohol Dependence 1:20 Cocaine Use Cocaine Dependence 1:5 Heroin Use Heroin Dependence 1:2 Illicit Use of Pain Medication Pain Medication Dependence 1:12 ~ 162 million ~ 6 million ~ 0.55 million ~ 12 million SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2004 and 2005
11 A Growing Concern: Illicit Use of Prescription Opioids 20% Ages 18 to 25 15% 10% Ages 12 to 17 5% 0% The New York Times Saturday, October 18, 2003 source: Food and Drug Administration NSDUH 2004
12 National Survey on Drug Use and Health: Minnesota Estimated Numbers of Persons Aged 12 or Older Needing But Not Receiving Treatment in the Past Year: Illicit Drugs: 104,000 Alcohol: 354,000 SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2004 and 2005
13 Kreek et al., 2000 Factors Contributing to Addiction use of the drug of abuse essential (100%) Genetic Environmental Drug-Induced Effects
14 Continuum of Risk
15 Kaij 1957; Kendler et al Twin Studies of Alcoholism 1957 Kaij Identical twins had similar severity 1997 Kendler et al Swedish twin-pairs born Concordance greater in MZ than DZ
16 Adoption and Alcoholism 4x risk if biological parent alcoholic 9x risk for moderate alcohol abuse if biological father had it Cloninger et al. 1981
17 Bipolar disorder Asthma Schizophrenia Heritability Alcohol dep. HTN CAD Cocaine dep. DM2 Opiate dep. MDD
18 Environment
19 Dopamine D2 Receptor in Monkeys Morgan et al., 2002
20 Social Rank and Effect of Prolonged Cocaine Use on Dopamine D2 Receptor Cocaine use Cocaine abstinence Czoty et al., 2004; Nader and Czoty 2005
21 Pharmacology
22 Impact of Short-Acting Heroin As Used on a Chronic Basis in Humans Functional State (Heroin) "High" "Straight" "Sick" (overdose) AM PM AM PM AM Days Dole, Nyswander and Kreek, 1966
23 Disruptions Induced by the On-Off of Drugs of Abuse levels of gene expression receptor mediated events physiology behaviors
24 Acute Opiate Effects on Endocrine Function in Humans Inhibition of release of ACTH Altered release of cortisol Inhibition of release of LH Lowered levels of testosterone Increased release of vasopressin Increased release of prolactin
25 Goals and Rationale for Specific Pharmacotherapy for an Addiction 1. Prevent withdrawal symptoms 2. Reduce drug craving 3. Normalize any physiological functions 4. Target treatment agent to specific site of action affected by drug of abuse
26 Characteristics of an Effective Addiction Medication Orally effective Slow onset of action Long duration of action Slow offset of action
27 Heroin versus Methadone versus Buprenorphine* Heroin Methadone Buprenorphine Route intravenous oral sublingual Onset immediate 30 minutes 30 minutes Duration 3 6 hrs hrs 36 hours Euphoria 1 2 hrs none none Withdrawal after 4 hrs after 24 hrs after 36 hours * effects of high dosages in tolerant individuals
28 Impact of Short-Acting Heroin versus Long-Acting Methadone Administered
29 Steady-State Methadone Administration in the Rat No Disruption of Stress Response Related Gene Expression (mrna Levels) CRF mrna CRF- R1 Receptor mrna POMC mrna Mu opioid receptor mrna Unterwald et al., 1995 ; Zhou et al., 1996;
30 Stable Dosing Reduce/eliminate withdrawal Reduce/eliminate craving Restore physical function Minimize side-effects No such thing as high or low doses only doses that work Generally between mg/day Not all issues are solved by changing dose
31 HFA Methadone Clinic 100 Opiate % Utox positive Week
32 Kaplan-Meier Curve of Cumulative Retention in Treatment Remaining in treatment (nr) Control Buprenorphine Treatment duration (days) Kakko et al. 2003
33 Buprenorphine Clinical Trials Buprenorphine superior to placebo Buprenorphine high dose v methadone high dose Equivalency Buprenorphine low dose v methadone low dose Equivalency Buprenorphine flex dose v methadone flex dose Equivalency Mattick et al. 2003
34 Breen et al. 2003; Gandhi et al. 2003; Lintzeris et al 2002; Umbricht et al Buprenorphine for Detoxification Withdrawal symptoms alleviated Not clearly easier than methadone Both buprenorphine and methadone taper associated with relapse rates >70% 90% of HFA buprenorphine maintenance patients failed previous short-term buprenorphine detoxification Maintenance is the model
35 Drug Use in Long-Term Methadone Maintained Patients v. Heroin Addicts Ongoing drug of abuse: Alcohol abuse Cocaine use Benzodiazepine use Marijuana use Active Parenteral Heroin Addicts (n=56) 64% 88% 18% 60% Long-Term Methadone Maintained Former Heroin Addicts (n=110) 13% 17% 7% 18% Novick et al., Drug and Alc. Depend., 33:235, 1993
36 Comparison of Relapse Rates Between Drug Addiction and Other Chronic Illnesses SOURCE: McLellan et al, JAMA 284: , Percent of patients who relapse 40-60% 30-50% 50-70% 50-70% Drug Addiction Type I Diabetes Hypertension Asthma Relapse rates for drug-addicted patients are compared with rates for those suffering from diabetes, hypertension and asthma. Relapse is common and similar across these illnesses (as is adherence to medication). Thus, drug addiction should be treated like any other chronic illness, with relapse serving as a trigger for renewed intervention.
37 Natural history of opiate addiction Lexington study of opiate addicts admitted (n=4766) 6 month to 5 year follow up after discharge Voluntary patients (n=272) Intention to treat: 82.9% failed 17.1% met treatment goal 19.3% lost to follow up 10.8% dead 52.8% relapse Average time to relapse 25.1 months 17.1% abstinent Pescor, 1943
38 Natural history of opiate addiction Lexington study of New York City addicts admitted in 1952 (n=100) 20 year follow up Intention to treat 68% failed 32% met treatment goal 10% lost to follow up 23% dead 25% relapse Average 7 hospitalizations, 8 imprisonments, average 4 years institutionalized Voluntary abstinence rate : 3% Voluntary abstinence rate : 67% Vaillant 1973
39 Natural History of Opiate Addiction California study of 581 male heroin addicts admitted (n=581) Drug overdose 21.6% Liver disease 15.2% Murder Suicide 19.5% Accident Hser et al. 2001
40 Natural History of Opiate Addiction Best abstinence-based treatment available 83% failed within 2 years Short-term methadone 80% failed within 2 years Gradual taper off of methadone 3.5 x death in first 2 years compared to those kept on methadone Pescor, 1943; Vaillant 1973; Woody 2007
41 Addiction s Other Diseases Early treatment reduces hepatitis C and HIV risk 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% HCV HIV-1 < >50 Age at admission into MMT (years) Piccolo et al. 2002
42 Opiate Addiction Treatment Methadone Buprenorphine Idaho Montana North Dakota South Dakota
43 Methadone Myths Does not eat your bones Does not rot your teeth Methadone is a legal addiction Addiction is maladaptive behavior Methadone maintenance restores behavior Methadone withdrawal is the worst Methadone makes you dumb Functional cognitive ability remains intact
44 A functional patient on methadone
45 Cost of Opiate Addiction versus Treatment Annual Cost per Person $314,000-$350,000 Liver transplantation $100,000-$200,000 Last 2 years of AIDS $100,000 Street or blue collar crime by a cocaine or heroin addict $30,000-$70,000 Prison (state or federal) $20,000-$100,000 Residential drug-free programs $4,055 at HCMC Methadone maintenance treatment program with onsite counseling and access to medical and psychiatric care
46 Methadone Maintenance Treatment Effect on Criminality Dole et al Dole et al. 1968
47 Methadone and Prisoners 197 Prerelease Counseling +referral Counseling + transfer Counseling + methadone 8% entered treatment 50% entered treatment 69% entered treatment 29% reincarcerated 33% reincarcerated 13% reincarcerated
48 Components of Comprehensive Drug Abuse Treatment HOUSING/ TRANSPORTATION FAMILY SERVICES CHILD CARE SERVICES INTAKE PROCESSING/ ASSESSMENT VOCATIONAL SERVICES MENTAL HEALTH SERVICES BEHAVIORAL THERAPY & COUNSELING TREATMENT PLAN SUBSTANCE USE MONITORING CLINICAL AND CASE MANAGEMENT PHARMACOTHERAPY SELF-HELP/PEER SUPPORT GROUPS FINANCIAL SERVICES CONTINUING CARE MEDICAL SERVICES LEGAL SERVICES AIDS/HIV SERVICES EDUCATIONAL SERVICES NIDA, 2000
49 Accessing Methadone Treatment Placement via Rule 25 Dual placement allowed Most 3 rd party payors cover Medicaid does not cover
50 Accessing Methadone Treatment Access available within 14 days Emergency/priority placement for Pregnancy HIV positive Medically ill CSAT: DHS website
51 Adequate Dosing It is never a matter of medication or behavioral change
52 Standards of Care What is our standard of care?
Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More informationBuprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationNoel Schenk MD. Davis Behavioral Health
Noel Schenk MD Davis Behavioral Health Michael Botticelli Director of National Drug Control Policy What is Addiction? Addiction is defined as a chronic, relapsing brain disease that is characterized by
More informationTHE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.
THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.
More informationOpioid Treatment in North Carolina SEPTEMBER 13, 2016
Opioid Treatment in North Carolina SEPTEMBER 13, 2016 Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among Past Year Users Aged 12 or Older: 2007 Source Where Respondent Obtained
More informationThe available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More informationclinic in Israel: disease incidence
15 years of Methadone Maintenance Treatment clinic in Israel: Drug abuse abstinence and minimal infectious disease incidence Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse Treatment & Research Tel-Aviv
More informationMethadone Maintenance Treatment for the Opioid Dependent Patient
Methadone Maintenance Treatment for the Opioid Dependent Patient Janice F. Kauffman RN, MPH, CAS, LADC1 Assistant Professor of Psychiatry, Harvard Medical School V. P., Addiction Treatment Services, North
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationMedications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives
More informationCSAM-SCAM Fundamentals. Cocaine Basics. Presentation provided by David C. Marsh MD CCSAM
CSAM-SCAM Fundamentals Cocaine Basics Presentation provided by David C. Marsh MD CCSAM Chronic Illness Relapsing & Remitting in Course Genetic Predisposition Individual Choice a Factor Environmental Influence
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationPharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
More informationThe Importance of Psychological Treatment and Behavioral Support
The Importance of Psychological Treatment and Behavioral Support Michael W. Otto, PhD Department of Psychological and Brain Science Boston University Conflicts and Acknowledgements No industry funding
More informationTreatment Can Work. SELECT A TOPIC...
Page 1 of 8 SELECT A TOPIC..... NIDA Home > Drug Abuse and Addiction: One of America's Most Challenging Public Health Problems Treatment Can Work Drug Treatment Works Research has revealed a number of
More informationOpioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity
Opioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity Holly Hills, Ph.D. June 13, 2017 Department of Mental Health Law and Policy Overview: Persons who have not been in
More informationMedication Assisted Treatment. Nicole Gastala, MD
Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants
More informationNational Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says
National Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says Last Updated February 2016 https://www.drugabuse.gov 1 Table of Contents Understanding Drug Abuse and Addiction:
More informationThe CARA & Buprenorphine Prescribing for APNs & PAs
The CARA & Buprenorphine Prescribing for APNs & PAs William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP FIAAN Assistant Clinical Professor, Drexel University, Philadelphia, PA V. P. & Chief Clinical Officer,
More informationMethadone Maintenance 101
Methadone Maintenance 101 OTP/DAILY DOSING CLINICS - ANDREW PUTNEY MD Conflicts of Interest - Employed by Acadia HealthCare 1 Why Methadone? At adequate doses methadone decreases opioid withdrawal symptoms
More informationTreating Opioid Use Disorders: An Update for Counselors and Other Providers
Treating Opioid Use Disorders: An Update for Counselors and Other Providers Brad Shapiro, MD Medical Director Opiate Treatment Outpatient Program Zuckerberg San Francisco General THE DOSING WINDOW HISTORICAL
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More informationPITTSBURGH MERCY: COMPREHENSIVE INTEGRATED CARE JUNE 6, 2018
PITTSBURGH MERCY: COMPREHENSIVE INTEGRATED CARE JUNE 6, 2018 AN ENHANCED MEDICAL HOME MODEL FOR THE SMI POPULATION Comprehensive Care Patient Centered Care Coordinated Care Accessible Services Quality
More informationWasted AN INTRODUCTION TO SUBSTANCE ABUSE
Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Dr. Brian L. Bethel Child and Family Therapist Independent Trainer and Consultant LPCC-S, LCDC III, RPT-S www.brianlbethel.com INTERPLAY COUNSELING & CONSULTING
More informationMedication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.
Slide #1 Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale AIDS Program Medical Director South Central Rehabilitation
More informationState Targeted Opioid Response Initiative (STORI) Fee-for-Service (FFS) Open Enrollment
State Targeted Opioid Response Initiative (STORI) Fee-for-Service (FFS) Open Enrollment DEPARTMENT OF HUMAN SERVICES (DHS) DIVISION OF MENTAL HEALTH & ADDICTION SERVICES (DMHAS) STORI INFORMATIONAL WEBINAR
More informationPennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story
Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story Sarah Sharfstein Kawasaki, MD Director of Addictions Services, Pennsylvania Psychiatric
More informationHealth Systems and Addiction: Provider Issues
Health Systems and Addiction: Provider Issues The Emerging Roles of Primary Care Patrick G. O Connor MD, MPH Dan and Amanda Adams Professor of General Medicine Chief, General Internal Medicine Yale University
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationAN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE
AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE Valerie Carrejo, MD Assistant Professor UNM Family Medicine Advances in Primary Care April 14, 2017 Objectives Review the basic
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More informationADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
More informationOpioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
More informationMAT - ICAAD 2018 Ron Jackson, MSW, LICSW
The ATTC Network Ten Regional Centers northwest@attcnetwork.org www.attcnetwork.org/northwest phone. 206-685-4419 1107 NE 45 th St, Ste 120, Seattle, WA 98105 http://attcnetwork.org/northwest U.S. Opioid
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationRationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers
Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers Marwan S. Haddad, M.D. Community Health Center, Inc. Connecticut September 16, 2008 Community Health Center, Inc.
More informationMethadone Treatment. in federal prison
INFORMATION FOR FEDERAL PRISONERS IN BRITISH COLUMBIA Methadone Treatment in federal prison This booklet will explain how to qualify for Methadone treatment in prison, the requirements of the Correctional
More informationThe Role of Urgent Care in responding to the opioid Crisis
The Role of Urgent Care in responding to the opioid Crisis Robert S Crausman MD MMS Partner, Ocean State Urgent Care and Primary Care Centers Clinical Professor of Medicine, Brown Rob@OSUC.net Opioid Crisis
More informationOpioid dependence: Detoxification
Opioid dependence: Detoxification What is detoxification? A. Process of removal of toxins from the body? B. Admitting a drug dependent person in a hospital and giving him nutrition? C. Stopping drug use
More informationOpioids Research to Practice
Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose
More informationImproving Outcomes in Methadone Treatment
Improving Outcomes in Methadone Treatment Cognitive/Behavioral Treatment Contingency Management Michael J. McCann, MA Matrix Institute on Addictions COMP Symposium September 11, 2007 Overview of Presentation
More informationAppendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
More informationOpioids Research to Practice
Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education
More informationMethadone Treatment. in federal prison
INFORMATION FOR FEDERAL PRISONERS IN BRITISH COLUMBIA Methadone Treatment in federal prison This booklet will explain how to qualify for Methadone treatment in prison, the requirements of the Correctional
More informationMedication Assisted Treatment:
Medication Assisted Treatment: A Training For Multidisciplinary Addiction Professionals Module III Medications 101 Goals for Module III This module reviews the following: Overview of three medications
More informationManagement of Opioid Use Disorder in Primary Care
1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,
More informationTHE STATE OF MEDICINE IN ADDICTION RECOVERY
OVERVIEW: Review addiction stats and trends Define addiction Explain neurobiology of addiction Review treatments of addiction Addiction Definition: A Primary, chronic, relapsing disease of brain reward,
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationJohn Murphy DO, MS Lynx Healthcare
Addiction to Pain Medication and Treatment John Murphy DO, MS Lynx Healthcare No Disclosures Objectives 1 Understand basic neurobiology and learning theory around opioid addiction 2 Identify aberrant behavior
More informationManagement Options for Opioid Dependence:
Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice
More informationThe Methadone Awareness Test*
The Methadone Awareness Test*!" #!$# # #%!&# %# #!! *The Methadone Awareness Test has been updated from the website. ' (!) %##% #! '! * ##" # ##! ' %#% %!% %#+%#%!,% %# #!, %%# %!'%%#%, %## % #!,% %!'
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationPublic Policy Statement on the Regulation of Office-Based Opioid Treatment
Public Policy Statement on the Regulation of Office-Based Opioid Treatment Background Office-based opioid treatment (OBOT) commonly refers to outpatient treatment services provided outside of licensed
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More informationDisclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.
Evolving Treads in Medication Assisted Treatment Christopher J Davis D.O. CAADC, FASAM Medical Director, The Ranch of Pennsylvania Medical Director, Pyramid Healthcare Diplomate of The American Board of
More informationIn 2008, an estimated 282,000 persons
National Survey of Substance Abuse Treatment Services The N-SSATS Report January 28, 2010 Similarities and Differences in Opioid Treatment Programs that Provide Methadone Maintenance or Buprenorphine Maintenance
More informationModels of good practice in drug treatment in Europe. Project group
Models of good practice in drug treatment in Europe ( moretreat 2006329 ) Project group Hamburg, London, Rome, Stockholm, Vienna, Warsaw, Zurich Project duration: 17 months from April 2006 August 2008
More informationOpioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative
Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative John W. McIlveen, Ph.D., LMHC, State Opioid Treatment Authority, Oregon Health Authority, Addictions and Mental Health Division
More informationPlace of addiction-informed comprehensive treatment in HIV care
Place of addiction-informed comprehensive treatment in HIV care Cecile Denis, PhD Center for Studies of Addiction, University of Pennsylvania, Philadelphia, USA University of Bordeaux, Bordeaux, France
More informationShould buprenorphine be covered for maintenance treatment in opioid dependent persons?
Prepared by: Silvia Pregno May 13,2012 Patients: people with opioid dependence Should buprenorphine be covered for maintenance treatment in opioid dependent persons? Intervention: buprenorphine Comparison:
More informationIntNSA Webinar Series
BUPRENORPHINE CLINIC: A MULTIDISCIPLINARY MODEL FOR OPIOID MAINTENANCE THERAPY Stephen Strobbe, PhD, RN, NP, PMHCNS-BC, CARN-AP Monday, June 4, 2012 IntNSA Webinar Series Funding for this webinar was made
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationTrends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville
Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted
More informationNorth American Opiate Medication Initiative (NAOMI)
North American Opiate Medication Initiative (NAOMI) Multi-Centre, Randomized Controlled Trial of Heroin-Assisted Therapy for Treatment- Refractory Injection Opioid Users File Number: 9427-U0146-75C CTA
More informationPOLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE MARK DUNCAN, MD November 8, 2018 SPEAKER
More informationMAT in the Corrections Setting
MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on
More informationMedication Assisted Treatment: Buprenorphine Clinical Coverage Policy 8A-3 Amended Date: 10/1/2015 DRAFT Table of Contents
Medication Assisted Treatment: Buprenorphine Clinical Coverage Policy 8A-3 10/1/2015 Table of Contents 1.0 Description of the Procedure, Product, or Service... 3 1.1 Definitions... 3 2.0 Eligibility Requirements...
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationThe causes of misuse:
The Drug Misuse The causes of misuse: Availability of drugs. A vulnerable personality. Adverse social environment. Regular drug taking play a role. Determining misuse and dependence, it is unclear whether
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationOptimizing Suboxone in Opioid Addicts
Optimizing Suboxone in Opioid Addicts David Chim, D.O. Integrated Substance Abuse Programs Dept. of Psychiatry, UCLA K30 Translational Research Interest March 24, 2009 dchim@mednet.ucla.edu www.uclaisap.org
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationHarm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD
Harm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD Objectives Provide an overview of harm reduction by defining shared language and key terms. Collaboratively
More informationBrief History of Methadone Maintenance Treatment
METHADONE Brief History of Methadone Maintenance Treatment Methadone maintenance treatment was on the cusp of the social revolution in the sixties. Doctors and public health workers had concluded what
More informationNational Opioid Treatment Guideline Dr. Ronald Lim
National Opioid Treatment Guideline Dr. Ronald Lim (MD, CCFP, DFASAM, ABAM(D), FISAM, CCSAM, MRO) Clinical Assistant Professor, Department of Psychiatry and Family Practice Cumming School of Medicine University
More informationOpioid Overdose Epidemic A Crises and Opportunity
Opioid Overdose Epidemic A Crises and Opportunity Samuel M. Silverman MD, FAPA, DFASAM Assistant Clinical Professor, UConn Medical School Director, Medical Education Rushford, A Hartford HealthCare Partner
More informationJohann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works
From the street to the NICU Richard Christensen, PA, CAS Johann Hari Treatment works Truths Disconnect with pregnant women seeking treatment Disconnect between community and science Medication is not a
More informationMedication Treatment and Opioid Use Disorder
Medication Treatment and Opioid Use Disorder Colleen T. LaBelle, MSN, RN-BC,CARN Program Director, Office-Based Addiction Treatment Director, STATE OBOT-B Boston Medical Center Disclosures I have no disclosures
More informationS 2356 SUBSTITUTE A AS AMENDED ======== LC004564/SUB A/3 ======== S T A T E O F R H O D E I S L A N D
0 -- S SUBSTITUTE A AS AMENDED LC00/SUB A/ S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 0 A N A C T RELATING TO HEALTH AND SAFETY -- INSURANCE--MENTAL ILLNESS AND SUBSTANCE
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationDeveloped and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services
Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop
More informationNational Conference of State Legislators
National Conference of State Legislators Mark W. Parrino, M.P.A. Monday, July 20, 2009 Philadelphia, PA Medication Assisted Treatment for Opiate Addiction In the Criminal Justice System Updated August
More informationTreating Addiction as a Chronic Illness: Why it is Finally Possible. A. Thomas McLellan Treatment Research Institute
Treating Addiction as a Chronic Illness: Why it is Finally Possible. A. Thomas McLellan Treatment Research Institute 9/29/2014 Treatment Research Research Institute, Institute, 20132012 The End Because
More informationSW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass
SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full
More informationBuprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
More informationBuprenorphine and MAT 101
Buprenorphine and MAT 101 Why is Medication Assisted Treatment so Important for Recovery? KEN SAFFIER, MD 7 TH ANNUAL INTEGRATION SUMMIT DECEMBER 8, 2016 Disclosures: u Ken Saffier, MD, has nothing to
More informationDrug Abuse Trends Minneapolis/St. Paul, Minnesota
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp Drug Abuse Trends Minneapolis/St.
More informationSubstance Abuse Level of Care Criteria
Substance Abuse Level of Care Criteria Table of Contents SUBSTANCE ABUSE OUTPATIENT: Adolescent... 3 SUBSTANCE ABUSE PREVENTION: Adult... 7 OPIOID MAINTENANCE THERAPY: Adult... 8 SUBSTANCE ABUSE INTERVENTION:
More informationMaternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC
Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Objectives 1. Discuss the effects of opiate addiction on mothers and infants. 2. Discuss a Medical Home
More informationBuprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction
Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction The Problem The overdose death rate in Missouri and in the country has been rising for
More informationMedication Assisted Treatment of Substance Use Disorders
3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard
More informationS 0332 S T A T E O F R H O D E I S L A N D
LC00 01 -- S 0 S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 01 A N A C T RELATING TO HEALTH AND SAFETY - COMPREHENSIVE DISCHARGE PLANNING Introduced By: Senators Miller,
More informationSubstance Abuse Suboxone Treatment
Substance Abuse Suboxone Treatment Program Waterbury Hospital Infectious Disease Clinic Richard Smith, LCSW Leonard Savage, Consumer Steven I. Aronin, MD FACP, Program Director Ryan White All Grantee Meeting
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #468 (NQF 3175): Continuity of Pharmacotherapy for Opioid Use Disorder (OUD) National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Prevention and Treatment of Opioid
More information